抗体-药物偶联物
药品
淋巴瘤
细胞毒性T细胞
癌症研究
单克隆抗体
抗原
医学
布仑妥昔单抗维多汀
抗体
弥漫性大B细胞淋巴瘤
药理学
免疫学
化学
霍奇金淋巴瘤
体外
生物化学
作者
Gulrayz Ahmed,Mehdi Hamadani,Taha Al‐Juhaishi
标识
DOI:10.1080/14712598.2025.2453524
摘要
Introduction Antibody-drug conjugates (ADCs) are a rapidly evolving class of anti-cancer drugs with a significant impact on management of hematological malignancies including diffuse large B-cell lymphoma (DLBCL). ADCs combine a cytotoxic drug (a.k.a. payload) attached through a linker to a monoclonal antibody specific to a particular cancer antigen. Payloads include microtubule disruptors or DNA damaging chemicals. After attaching to the antigen, the ADCs are internalized, and the payload is dissociated from ADC by lysozymes and delivered to the intended site for exerting cytotoxic effects. This unique molecular design permits a better balance of efficacy and safety. Loncastuximab tesirine and polatuzumab vedotin are two ADCs approved in the U.S.A. for treatment of DLBCL.
科研通智能强力驱动
Strongly Powered by AbleSci AI